Pyxis Oncology Names Thomas Civik CEO and Board Chair

Evidence Leadership source gap catch-up · Effective September 4, 2026 · Discovery September 8, 2026 · Importance 4/5 · Direction Neutral Summary Pyxis Oncology appointed Thomas Civik permanent Chief Executive Officer and Chairman of the Board effective September 4, 2026. Civik had served as interim…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

BMS – Anthropic AI Partnership
J&J Secures Option on Sail’s In Vivo CAR-T Platform
Gossamer Bio Ties $250 Million Financing to FDA Milestones After Mixed PROSERA Result
Ipsen to Acquire Memo Therapeutics for Up to EUR700M